Citations

Clear

9383 citation(s) found for "Thomas, PS".

A-373 Comparison of the CoaguChek ® and Coag-Sense ® PT2 Meter Point of Care INR Devices
Schumann, Thomas L. , Karon, Barry L., O’Connor, Clare , Jennifer, L, Blanco, J, Hartman, Lisa L.R., Uy, J. , Myhre, Nikki K., GAYLE, DAVID D., Hartung, K, David, H., Santrach, Paula J., O'Connor, C, Jennifer, L, Kramer, A, Hartung, K, David, H, McBane, Robert D.

Mayo Clinic

Clinical Chemistry | September 27, 2023 | Volume: 69 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvad097.329 Get It

Abstract Background Warfarin monitoring may be done at the point-of-care (POC) at home, in a clinic environment, or be performed using plasma specimens in a central laboratory. With a goal of standardizing International Normalization Ratio (INR) measurements and improving data integrity by enabling electronic transmission of results from any location, we evaluated two POC INR devices against an internal plasma INR reference method. Methods We conducted a multicenter study to test the accuracy of two commercially available point of care devices: Coag-Sense PT2 Meter (Coagusense, Inc., Fremont, CA) and CoaguChek XS Pro or XS Plus (Roche Diagnostics, Indianapolis, IN) compared with plasma INR values among warfarin treated patients. Bias and linear regression analysis were assessed for device-plasma INR comparisons. Warfarin dosing decisions were assessed for each device compared to an internal plasma INR reference method (Instrumentation Laboratories ACLTOP 500, 550, 750 analyzers (Werfen Diagnostics, Bedford MA) in one of three CLIA-certified laboratories. The thromboplastin used at our institution for INR measures is HemosIL RecombiPlasTin 2G (R2G) reagent (Werfen Diagnostics, Bedford MA) which has an International Sensitivity Index (ISI) of 1.0. Results Two hundred ninety-nine warfarin patients treated across three Mayo Clinic sites agreed to participate in the study. Common anticoagulant indications were atrial fibrillation (63.9%), venous thromboembolism (21.7%) and heart valve prosthesis (15.4%) with a 2.0–3.0 INR target range for 93.6% of patients. For the CoaguChek devices, 81.3% of values fell within 0.2 INR units of plasma INR referent and 95.3% within 0.4 units. The correlation between CoaguChek whole blood and plasma INR was excellent (R2 = 0.93). For the Coag-Sense device, 34.1% of values fell within 0.2 INR units and 60.2% within 0.4 INR units of plasma INR values, with a slightly weaker correlation between Coag-Sense whole blood and plasma INR (R2 = 0.83; P < 0.0001). Mean (± standard deviation) deviation from plasma INR was 0.04 ± 0.2 for CoaguChek compared to 0.4 ± 0.3 for Coag-Sense (P < 0.0001). The difference between POC devices was largely attributed to systematic negative bias between Coag-Sense and ACL TOP plasma INR values. Using the plasma INR as the reference method for dosing decision making, appropriate dosing recommendations would have occurred for 97.7% of CoaguChek and 81.6% of Coag-Sense results. Conclusion Compared to our institution's plasma reference method, INR values obtained from the CoaguChek devices (XS Pro and XS Plus) exhibited less systematic bias compared to the Coag-Sense values. This translates to greater percentage of concordant management decisions between POC and laboratory plasma INR methods when the CoaguChek device is used.
B-069 Performance Evaluation of a Ma2 Autoantibodies ELISA
Gorsh, Amy P., Kryzer, Thomas J., Mills, John R. , McKeon, Andrew , Pittock, Sean J.

Mayo Clinic

Clinical Chemistry | September 27, 2023 | Volume: 69 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvad097.408 Get It

Abstract Background Ma-2 is a neuronal nucleolar protein with purported involvement in RNA transcription and apoptosis regulation. Patients with Ma2 antibodies present with autoimmune encephalitis (limbic or brainstem). Ma-2 antibodies are a high-risk marker for paraneoplastic neurologic cause for autoimmune encephalitis (>75% of patients having either testicular cancer or non-small cell lung cancer). In older patients, there is a higher frequency of small cell lung cancer or other cancers especially when Ma 1 antibodies are also detected. Identification of Ma2 antibodies is important to help diagnose autoimmune encephalitis, guide the cancer search and aid treatment selection. The objective of this study was to develop and document the performance of a qualitative enzymatically amplified sandwich-type Ma2 Antibody ELISA. Methods The Ma2 ELISA was produced in-house utilizing commercially available protein and was performed on a Hamilton Star liquid handling instrument equipped with a plate washer and plate reader. Each assay plate included patient samples along with 3 independent negative serum calibrators and 4 quality controls (Both positive and negative controls per matrix [CSF or serum]) each tested in duplicate. Mean optical densities (OD) for patient specimens were compared to the average OD of the negative serum calibrators to generate a ratio. A ratio cut-off of 8 was selected for reporting positivity based on preliminary studies and was validated during the method performance assessment. To assess assay performance we measured precision (3 positive pools at or above the cut-off ratio for each specimen type were tested 20 times in one assay and in duplicate across 10 independent assays), accuracy comparing to the current reference method at Athena® Diagnostics (N = 10 positives / 40 negatives), analytical specificity (20 samples with high titer autoantibodies directed against other proteins), and the impact of common interferences (lipids, bilirubin, hemolysate were spiked into 2 positive and 1 negative sample per interference). Clinical performance of the assay for differentiating healthy donors without disease (N = 140) and those with non-Ma2 neurological autoimmunity (N = 23) from those with clinical phenotypes consistent with Ma-2 associated encephalitis (N = 8) was measured. Results Serum intra-assay imprecision (coefficient of variation; %CV) ranged from 3.0–6.5%. Inter-assay imprecision ranged from 21–29%. CSF intra-assay imprecision ranged from 3.5–10%. Inter-assay imprecision ranged from 13–15.5%. Accuracy was assessed via qualitative comparison to a reference method [western blot or nanoliter scale immunoassay]. There was perfect agreement between methods. To assess analytical specificity, samples with high concentrations of immunoglobulins (hypergammaglobulinemia [N = 10] or Systemic Lupus Erythematosus [N = 10]) were tested in serum (and spiked into CSF); all were negative. Interference studies were conducted on 2 positive Ma2 serum and CSF samples, spiked for highly hemolytic (1000 mg/dL), lipemic (2000 mg/dL) and icteric (60 mg/dL) conditions. All samples remained positive under given interferents. A negative sample was tested for each matrix, both remained negative. Clinical specificity was 100% with all samples from patients without Ma-2 encephalitis testing negative (N = 183). All ELISA positives identified in this study had phenotypes consistent with Ma-2 autoimmune encephalitis (N = 8). Conclusion The performance of the Ma2 ELISA was acceptable for clinical laboratory implementation.
Acute and Longer-Term Effects of COVID-19 on Auditory and Vestibular Symptoms
Berlot, Ashley , Moskowitz, Howard S. , Lin, Juan , Liu, Jianyou, Sehanobish, Esha , Jerschow, Elina , Ow, Thomas J. , Sussman, Elyse

Mayo Clinic

Otology & Neurotology | September 27, 2023 | Volume: 44 | Issue: 10 | Pages: 1100-1105

10.1097/mao.0000000000004027 | PMID 37758317 Get It

Objective To evaluate long-term effects of COVID-19 on auditory and vestibular symptoms in a diverse cohort impacted by the initial 2020 COVID-19 infection in the pandemic's epicenter, before vaccine availability. Study Design Cohort study of individuals with confirmed COVID-19 infection, diagnosed in the March–May 2020 infection wave. A randomized, retrospective chart review of 1,352 individuals was performed to identify those with documented new or worsening auditory (aural fullness, tinnitus, hyperacusis, hearing loss) or vestibular (dizziness, vertigo) symptoms. Those with documented symptoms (613 of the 1,352 initial cohort) were contacted for a follow-up telephone survey in 2021–2022 to obtain self-report of aforementioned symptoms. Setting Academic tertiary hospital system in Bronx, NY. Patients Adults 18 to 99 years old with confirmed COVID-19 infection, alive at time of review. One hundred forty-eight charts were excluded for restricted access, incomplete data, no COVID-19 swab, or deceased at time of review. Intervention Confirmed COVID-19 infection, March to May 2020. Main Outcomes Measures Auditory and vestibular symptoms documented in 2020 medical records and by self-report on 2021 to 2022 survey. Results Among the 74 individuals with documented symptoms during the first 2020 COVID-19 wave who participated in the 2021 to 2022 follow-up survey, 58% had documented vestibular symptoms initially in 2020, whereas 43% reported vestibular symptoms on the 2021 to 2022 survey (p = 0.10). In contrast, 9% had documented auditory symptoms initially in 2020 and 55% reported auditory symptoms on the 2021 to 2022 survey (p < 0.01). Conclusions COVID-19 may impact vestibular symptoms early and persistently, whereas auditory effects may have more pronounced long-term impact, suggesting the importance of continually assessing COVID-19 patients.
195: Utilization of ECMO in liver transplant patients: Pre-emptive vs rescue strategy, jury is still out!
Jena, Anek , Tawk, Rhoda, Kiley, Sean , Sanghavi, Devang , Lowman, Philip, Canabal, Juan, Archer, M. Elizabeth, Thomas, Mathew , Landolfo, Kevin , Sareyyüpoğlu, Başar , Guru, Pramod , Franco, Pablo Moreno , Bhattacharyya, Anirban, Chadha, Ryan , Aniskevich, Stephen , Archer, Martin, Taner, C. Burcin , Pham, Si M. , Chaudhary, Sanjay

Mayo Clinic

ASAIO Journal | September 27, 2023 | Volume: 69 | Issue: Supplement 3 | Pages: 19-19

10.1097/01.mat.0000990672.98322.30 Get It

Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Nakamura, Yoshiaki , Mizuno, Nobumasa , Sunakawa, Yu , Canon, Jean-Luc, Galsky, Matthew D. , Hamilton, Erika , Hayashi, Hidetoshi , Jérusalem, Guy , Kim, Seung Tae , Lee, Keun‐Wook , Fonkoua, Lionel Aurelien Kankeu , Monk, Bradley J. , Oh, Do‐Youn , Pohlmann, Paula R. , Reck, Martin , Shin, Sang Joon , Takahashi, Shunji , Groisberg, Roman , Ramos, Jorge , Tan, Sherry, Stinchcombe, Thomas E. , Bekaii‐Saab, Tanios , Kankeu Fonkoua, Lionel Aurelien, Nguyen, Danny , Oh, Do-Youn , Okines, Alicia , O'Malley, David M , Reck, Martin , Sudo, Kazuki , Takahashi, Shunji , Van Marcke, Cedric , Yu, Evan Y , Groisberg, Roman , Stinchcombe, Thomas E , Bekaii-Saab, Tanios S , Hamilton, Erika P , Mizuno, Nobumasa , Pohlmann, Paula , Jerusalem, Guy , Nakamura, Yoshiaki , Canon, Jean-Luc Re , O’Malley, David M.

Mayo Clinic

Journal of Clinical Oncology | September 26, 2023 | Volume: 41 | Issue: 36 | Pages: 5569-5578

10.1200/jco.23.00606 | PMID 37751561 Get It

PURPOSE To evaluate the efficacy and safety of tucatinib and trastuzumab in patients with previously treated human epidermal growth factor receptor 2–positive (HER2+) metastatic biliary tract cancer (mBTC). METHODS SGNTUC-019 (ClinicalTrials.gov identifier: NCT04579380 ) is an open-label phase II basket study evaluating the efficacy and safety of tucatinib and trastuzumab in patients with HER2-altered solid tumors. In the biliary tract cancer cohort, patients had previously treated HER2 overexpressing or amplified (HER2+) tumors (identified with local testing) with no prior HER2-directed therapy. The primary end point was confirmed objective response rate (cORR) per investigator assessment. Patients were treated on a 21-day cycle with tucatinib (300 mg orally twice daily) and trastuzumab (8 mg/kg intravenously followed by 6 mg/kg every 3 weeks). RESULTS Thirty patients were enrolled. As of data cutoff (January 30, 2023), the median duration of follow-up was 10.8 months. The cORR was 46.7% (90% CI, 30.8 to 63.0), with a disease control rate of 76.7% (90% CI, 60.6 to 88.5). The median duration of response and progression-free survival were 6.0 months (90% CI, 5.5 to 6.9) and 5.5 months (90% CI, 3.9 to 8.1), respectively. At data cutoff, 15 patients (50.0%) had died, and the estimated 12-month overall survival rate was 53.6% (90% CI, 36.8 to 67.8). The two most common treatment-emergent adverse events (TEAEs) were pyrexia (43.3%) and diarrhea (40.0%). Grade ≥3 TEAEs were reported in 18 patients (60.0%), with the most common being cholangitis, decreased appetite, and nausea (all 10.0%), which were generally not treatment related. TEAEs led to treatment regimen discontinuation in one patient, and there were no deaths due to TEAEs. CONCLUSION Tucatinib combined with trastuzumab had clinically significant antitumor activity and was well tolerated in patients with previously treated HER2+ mBTC.
Potential benefits of photon counting detector computed tomography in pediatric imaging
Yu, Lifeng , Esquivel, Andrea , Thorne, Jamison E. , Hull, Nathan C. , Weber, Nikkole M. , Thacker, Paul G. , Thomas, Kristen B. , Binkovitz, Larry A. , Horst, Kelly K. , Rajiah, Prabhakar Shanta, Baffour, Francis , Yu, Lifeng , McCollough, Cynthia H. , Rajiah, Prabhakar , Guérin, J. , Fletcher, Joel G.

Mayo Clinic

The British Journal of Radiology | September 26, 2023 | Volume: 96 | Issue: 1152 | Pages: No page available

10.1259/bjr.20230189 | PMID 37750939 Get It

Abstract Photon counting detector (PCD) CT represents the newest advance in CT technology, with improved radiation dose efficiency, increased spatial resolution, inherent spectral imaging capabilities, and the ability to eliminate electronic noise. Its design fundamentally differs from conventional energy integrating detector CT because photons are directly converted to electrical signal in a single step. Rather than converting X-rays to visible light and having an output signal that is a summation of energies, PCD directly counts each photon and records its individual energy information. The current commercially available PCD-CT utilizes a dual-source CT geometry, which allows 66 ms cardiac temporal resolution and high-pitch (up to 3.2) scanning. This can greatly benefit pediatric patients by facilitating high quality fast scanning to allow sedation-free imaging. The energy-resolving nature of the utilized PCDs allows “always-on” dual-energy imaging capabilities, such as the creation of virtual monoenergetic, virtual non-contrast, virtual non-calcium, and other material-specific images. These features may be combined with high-resolution imaging, made possible by the decreased size of individual detector elements and the absence of interelement septa. This work reviews the foundational concepts associated with PCD-CT and presents examples to highlight the benefits of PCD-CT in the pediatric population.
Nutrition Knowledge Of Firefighters
Nolte, Charles, Luedke, Joel, Erickson, Jacob L. , Zeller, Annette, Dobbs, Ward C. , Markert, Adam, Fields, Jennifer B. , Jones, Margaret T. , Zeller, Annette, Almonroeder, Thomas Gus , Jagim, Andrew R.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 26, 2023 | Volume: 55 | Issue: 9S | Pages: 471-471

10.1249/01.mss.0000984204.55589.9c Get It

Cross-validation Of The Army’s Body Fat Percent Estimation Formula Using A Three-compartment Model
Dobbs, Ward C. , Luedke, Joel, Carpenter, Makenna, Jacobson, Anna K., Schmitt, Rachel, Marquardt, Adriana, Jagim, Andrew R. , Almonroeder, Thomas Gus

Mayo Clinic

Medicine & Science in Sports & Exercise | September 26, 2023 | Volume: 55 | Issue: 9S | Pages: 370-371

10.1249/01.mss.0000983252.13761.ea Get It

Anesthesia and Critical Care for the Prediction and Prevention for Small-for-size Syndrome: Guidelines from the ILTS-iLDLT-LTSI Consensus Conference
Rajakumar, Akila , Shingina, Alexandra , Yoon, Uzung , Patel, Dhupal , Spiro, Michael , Bhangui, Pooja , Sun, Li-Ying, Humar, Abhinav , Findlay, James Y. , Saigal, Sanjiv , Rodríguez-Dávalos, Manuel I. , Kumar, Lakshmi , Kumaran, Vinay , Agarwal, Shaleen , Egawa, Hiroto , Lerut, Jan , Bröering, Dieter C. , Berenguer, Marina , Cattral, Mark S. , Clavien, Pierre‐Alain , Chen, Chao‐Long , Shah, Samir, Zhu, Zhi‐Jun , Ascher, Nancy L. , Emond, Jean C. , Rela, Mohamed , Findlay, James, Berenguer, Marina , Chadha, Ryan , Sakai, Tetsuro , Bezinover, Dmitri , Singh, Shweta A , Yi, Nam‐Joon , Berlakovich, Gabriela , Bhangui, Prashant , Rammohan, Ashwin

Mayo Clinic

Transplantation | September 26, 2023 | Volume: 107 | Issue: 10 | Pages: 2216-2225

10.1097/tp.0000000000004803 | PMID 37749811 Get It

Background. During the perioperative period of living donor liver transplantation, anesthesiologists and intensivists may encounter patients in receipt of small grafts that puts them at risk of developing small for size syndrome (SFSS). Methods. A scientific committee (106 members from 21 countries) performed an extensive literature review on aspects of SFSS with proposed recommendations. Recommendations underwent a blinded review by an independent expert panel and discussion/voting on the recommendations occurred at a consensus conference organized by the International Liver Transplantation Society, International Living Donor Liver Transplantation Group, and Liver Transplantation Society of India. Results. It was determined that centers with experience in living donor liver transplantation should utilize potential small for size grafts. Higher risk recipients with sarcopenia, cardiopulmonary, and renal dysfunction should receive small for size grafts with caution. In the intraoperative phase, a restrictive fluid strategy should be considered along with routine use of cardiac output monitoring, as well as use of pharmacologic portal flow modulation when appropriate. Postoperatively, these patients can be considered for enhanced recovery and should receive proactive monitoring for SFSS, nutrition optimization, infection prevention, and consideration for early renal replacement therapy for avoidance of graft congestion. Conclusions. Our recommendations provide a framework for the optimal anesthetic and critical care management in the perioperative period for patients with grafts that put them at risk of developing SFSS. There is a significant limitation in the level of evidence for most recommendations. This statement aims to provide guidance for future research in the perioperative management of SFSS.
Statistical Mechanics Metrics in Pairing and Parsing In Silico and Phenotypic Data of a Novel Genetic NFκB1 (c.T638A) Variant
Chaudhri, Eman N. , Abbott, Jessica M. , Islam, Naeyma N., Weber, Caleb A., Coban, Matt , Squire, Jacqueline D. , Mantia, Sarah, Wierenga, Klaas J. , Caulfield, Thomas R. , Coban, Mathew A , Bilgili, Ahmet , Caulfield, Thomas R , Abbott, Jessica M., Squire, Jacqueline , Fuller, Jessica M.

Mayo Clinic

Genes | September 24, 2023 | Volume: 14 | Issue: 10 | Pages: 1855

10.3390/genes14101855 | PMID 37895204 Get It

(1) Background: Mutations in NFκB1, a transcriptional regulator of immunomodulating proteins, are a known cause of inborn errors of immunity. Our proband is a 22-year-old male with a diagnosis of common variable immunodeficiency (CVID), cytopenias with massive splenomegaly, and nodular regenerative hyperplasia of the liver. Genetic studies identified a novel, single-point mutation variant in NFκB1, c. T638A p. V213E. (2) Methods: Next-generation panel sequencing of the patient uncovered a novel single-point mutation in the NFκB1 gene that was modeled using the I-TASSER homology-modeling software, and molecular dynamics were assessed using the YASARA2 software (version 20.14.24). (3) Results: This variant replaces valine with glutamic acid at position 213 in the NFκB1 sequence. Molecular modeling and molecular dynamic studies showed altered dynamics in and around the rel homology domain, ankyrin regions, and death domain of the protein. We postulate that these changes alter overall protein function. (4) Conclusions: This case suggests the pathogenicity of a novel variant using protein-modeling techniques and molecular dynamic simulations.